Business Context and Reporting Period
This Form 8-K reports on the 2015 Annual Meeting of Stockholders held by Aquinox Pharmaceuticals, Inc. on May 11, 2015. The meeting took place at the offices of Cooley LLP in Seattle, Washington. Note: The request metadata references "Neurogene Inc.," but the filing text explicitly identifies the registrant as Aquinox Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals. The certified voting results are as follows:
- Proposal No. 1: Election of Class I Directors
- David Main: 7,834,803 votes For; 4,245 votes Against; 493,588 Broker Non-Votes.
- Sean Nolan: 7,834,803 votes For; 4,245 votes Against; 493,588 Broker Non-Votes.
- Outcome: Both nominees were elected to serve until the 2018 Annual Meeting.
- Proposal No. 2: Ratification of Independent Auditor
- Auditor: Deloitte LLP for the fiscal year ending December 31, 2015.
- Votes: 8,330,852 For; 1,784 Against.
- Outcome: The selection was ratified.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. It is a procedural report of shareholder voting outcomes.
Important Facts for Investors to Verify
- Confirm the identity of the registrant as Aquinox Pharmaceuticals, Inc., distinct from Neurogene Inc. mentioned in the request metadata.
- Verify the successful election of directors David Main and Sean Nolan for the Class I director seats.
- Confirm the ratification of Deloitte LLP as the independent auditor for the 2015 fiscal year.
- Note the significant number of broker non-votes (493,588) on the director election proposal.